Highlights of This Issue 1363

SPECIAL FEATURES

CCR Translations

1365 Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required
Yaohua Xue and Piro Lito
See related article, p. 1471

CCR Perspectives in Regulatory Science and Policy

1368 An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur, and Reena Philip

Molecular Pathways

1373 Molecular Pathways: Mucins and Drug Delivery in Cancer
Chinthalapally V. Rao, Naveena B. Janakiram, and Altaf Mohammed

Review

1379 Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways
Adeeb Derakhshan, Zhong Chen, and Carter Van Waes

CANCER THERAPY: CLINICAL

1388 Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

1397 Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/ Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung-Min Lee, Cody J. Peer, Minshu Yu, Lauren Amable, Nicolas Gordon, Christina M. Aunnuziata, Nicole Houston, Andrew K.L. Goey, Tristan M. Sissung, Bernard Parker, Lori Minasian, Victoria L. Chiou, Robert F. Murphy, Brigitte C. Widemann, William D. Figg, and Elise C. Kohn

1407 Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual
Chad Tang, Kenneth R. Hess, Dwana Sanders, Suzanne E. Davis, Aman U. Buzdar, Razelle Kurzrock, J. Jack Lee, Funda Meric-Bernstam, and David S. Hong

1414 Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Chad Tang, Steven I. Sherman, Mellanie Price, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman Buzdar, George Wilding, and J. Jack Lee

PERSONALIZED MEDICINE AND IMAGING

1422 Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Christopher D. Hart, Alessia Vignoli, Leonardo Tenori, Gemma Leonora H, Ta Van To, Clement Adebamowo, Syed Mozammel Hossain, Laura Biganzoli, Emmanuela Risi, Richard R. Love, Claudio Luchinata, and Angelo Di Leo

1432 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Miguel Quintela-Fandino, Ana Lluch, Luis Manso, Isabel Calvo, Javier Cortes, Jose Angel Garcia-Saenz, Miguel Gil-Gil, Noelia Martinez-Janez, Antonio Gonzalez-Martin, Encarna Adrover, Raquel de Andres, Gemma Viñas, Antonio Lombart-Cussac, Emilio Alba, Juan Guerra, Begona Bermejo, Esther Zamora, Fernando Moreno-Anton, Sonia Pernas Simon, Alfredo Carrato, Antonio Lopez-Alonso, María José Escudero, Ruth Campo, Eva Carrasco, Jose Palacios, Francisca Muñero, and Ramon Colomer
CANCER THERAPY: PRECLINICAL

1442 Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules
Ying Liu, Yogandan Balagurunathan, Thomas Atwater, Sanja Antic, Qian Li, Ronald C. Walker, Gary T. Smith, Pierre P. Massion, Matthew B. Schabath, and Robert J. Gillies

1450 Identification of Keratin 19–Positive Cancer Stem Cells Associated Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Takayuki Kawai, Kentaro Yasuchika, Satoru Seo, Tatsuya Higashi, Takamichi Ishii, Yuya Mitsuhashi, Hidenobu Kojima, Ryoya Yamaoka, Hokahiro Katayama, Elena Yukie Yoshitohsi, Satoshi Ogiso, Sadahiko Kita, Katsutarou Yasuda, Ken Fukumitsu, Yuji Nakamoto, Etsuro Hatano, and Shinji Uemoto

1461 Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
Irina Heid, Katja Steiger, Marija Trajkovic-Arsic, Marcus Settles, Manuela R. Eßwein, Mert Erkan, Jörg Kleeff, Carsten Jager, Helmut Friess, Bernhard Haller, Andreas Steingässer, Roland M. Schmid, Markus Schwaiger, Ernst J. Rummenny, Irene Esposito, Jens T. Stiveke, and Rickmer F. Braren

1471 Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
See related commentary, p. 1365

CANCER THERAPY: PRECLINICAL

1481 UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Deborah DeRyckere, Alisa B. Lee-Sherick, Hannah A. Scarborough, Barbara A. Helfrich, Paul A. Bunn, and James DeGregori

1493 The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

1506 MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu, Chia-Ying K. Lam, Watana Long, Lusiana Widjaja, Yinhuai Yang, Hua Li, Linda Jin, Steve Burke, Sergey Gorlatov, Jennifer Brown, Ralph Alderson, Margaret D. Lewis, Jeffrey L. Nordstrom, Scott Koenig, Paul A. Moore, Syd Johnson, and Ezio Bonvini

1519 Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus
Mohanraj Ramachandran, Di Yu, Matheus Dyczynski, Sathishkumar Baskaran, Lei Zhang, Aleksei Lulla, Valeria Lulla, Síle Saul, Sven Nelder, Anna Dimberg, Andres Merits, Justyna LejaJarblad, and Magnus Essand

1531 AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
Hannah A. Scarborough, Barbara A. Helfrich, Martas Casás-Selvens, Alvin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik-Choon Tan, Daniel C. Chan, Zhiyong Zhang, Vadym Zaberezhnyy, Paul A. Bunn, and James DeGregori

1542 BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Iris Sze K. Luk, Raunak Shrestha, Hui Xue, Yuwei Wang, Fang Zhang, Dong Lin, Anne Haegert, Rebecca Wu, Xin Dong, Colin C. Collins, Amina Zoubeidi, Martin E. Gleave, Peter W. Gout, and Yuzhuo Wang

1552 Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

1564 Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Jingli Zhang, Swati Khanna, Qun Jiang, Christine Alewine, Markku Miettinen, Ira Pastan, and Rafii Hassan

Downloaded from clincancerres.aacrjournals.org on July 8, 2021. © 2017 American Association for Cancer Research.
BIOLOGY OF HUMAN TUMORS

1575 Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer
Tuan-Jie Li, Yu-Ming Jiang, Yan-Feng Hu, Lei Huang, Jiang Yu, Li-Ying Zhao, Hai-Jun Deng, Ting-Yu Mou, Hao Liu, Yang Yang, Qi Zhang, and Guo-Xin Li

1586 Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma
Phu Hung Nguyen, Julie Giraud, Lucie Chambonnier, Pierre Dubus, Linda Wittkop, Geneviève Belleanné, Denis Collet, Isabelle Soubeyran, Serge Evrard, Benoit Rousseau, Nathalie Senant-Dugot, Francis Mégraud, Frédéric Mazurier, and Christine Varon

1598 Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Joo Young Kim, Jacqueline A. Brosnan-Cashman, Soyeon An, Sung-Joo Kim, Ki-Byung Song, Min-Sun Kim, Mi-Ju Kim, Dae Wook Hwang, Alan K. Meeker, Eunsil Yu, Song Cheol Kim, Ralph H. Hruban, Christopher M. Heaphy, and Seung-Mo Hong

1607 Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Yi Zhong, Anne Marggregor-Das, Tyler Saunders, Martin C. Whittle, Alvin Makohon-Moore, Zachary A. Kohutek, Justin Poling, Brian T. Herbst, Breanna M. Javier, Leslie Cope, Steven D. Leach, Sunil R. Hingorani, and Christine A. Iacobuzio-Donahue

ABOUT THE COVER
The cover shows an area of a human pancreatic ductal adenocarcinoma with moderate tumor cellularity stained with Movat’s pentachrome staining visualizing tumor cells (red), intratumoral collagen fibres (yellow) and mucin/ground substance (blue). For details, see the article by Heid and colleagues on page 1461 of this issue.